Research programme: trasferrin conjugates - Panther Biotechnology

Drug Profile

Research programme: trasferrin conjugates - Panther Biotechnology

Alternative Names: Research programme: trasferrin conjugates - Faulk Pharmaceuticals

Latest Information Update: 22 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Faulk Pharmaceuticals
  • Developer Panther Biotechnology
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Parasitic infections; Viral infections

Most Recent Events

  • 16 Jul 2015 Panther Biotechnology acquires transferrin conjugates from Faulk Pharmaceuticals
  • 07 Apr 2015 Panther Biotechnology enters into a definitive agreement with Faulk Pharmaceuticals for the acquisition of doxorubicin transferrin conjugate
  • 07 Apr 2015 Preclinical trials in Autoimmune disorders, Viral infections and Parasitic infections in USA before April 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top